Minimal residual disease measured at the end of induction therapy may be a way of identifying children with B-cell precursor-acute lymphoblastic leukaemia (ALL) and late bone marrow relapse who will benefit the most from a stem cell transplantation, long term follow-up of the ALLR3 trial shows. The international open label randomised trial involved children with ...
MRD “highly prognostic” in kids with late relapsed B-cell precursor ALL
By Nicola Garrett
13 Mar 2019